Fig 2.

Clinically important (A) hematologic and (B) nonhematologic toxicities. A Pearson χ² test to assess the null hypothesis (ie, the probability of adverse events is independent of treatment) was statistically significant at P < .005 for grade 4 and worse neutropenia (absolute neutrophils count [ANC]) and thrombocytopenia (platelets [PLT]); grade 3 or worse hemoglobin (Hgb), infection/fever (fever), and GI toxicity; and grade 2 or worse peripheral neuropathy, pulmonary, and hepatic toxicity. CP, carboplatin and paclitaxel; CPG, carboplatin, paclitaxel, and gemcitabine; CPD, carboplatin, paclitaxel, and doxorubicin; CT-CP, carboplatin plus topotecan, then carboplatin plus paclitaxel; CG-CP, carboplatin plus gemcitabine, then carboplatin plus paclitaxel.